Cross-clade immune responses reported in South African RV144 HIV vaccine regimen

A promising HIV vaccine shows signs of cross-protective benefits
Professor Glenda Gray, CEO and President of the South African Medical Research Council, CoPI of the HIV Vaccine Trials Network. This material relates to a paper that appeared in the Sep. 18, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by G.E. Gray at University of the Witwatersrand in Johannesburg; South Africa; and colleagues was titled, "Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa." Credit: ©South African Medical Research Council

Despite major breakthroughs in HIV prevention and treatment, there were an estimated 1.8 million people newly infected with HIV in 2018, and an estimated 5,000 new HIV infections around the world every day. The pursuit for a safe, effective and scalable HIV vaccine, although a challenging endeavor, is a global imperative.

The results of a study titled "Immune correlates of the Thai RV144 vaccine regimen in South Africa," led by Dr. Glenda Gray, co-principal investigator of the HIV Vaccine Trials Network (HVTN), have been published in the journal Science Translational Medicine. The study was conducted in South Africa using the same HIV vaccine regimen that showed modest protection in an efficacy study conducted in Thailand, where clades B and E are prominent. Although clade C is the dominant circulating strain of HIV in South Africa, the RV144/Thai vaccine regimen mounted significant cellular and antibody responses in study participants enrolled in South Africa.

Gray and her team evaluated whether the vaccine-induced immune responses would be similar in a South African cohort if immunized with the same RV144 HIV vaccine regimen used in Thailand. The U.S. Army-led RV144 was the first vaccine clinical trial ever to demonstrate any efficacy in preventing HIV. The regimen is a heterologous "prime-boost" combination of two vaccines: ALVAC-HIV and AIDSVAX B/E, based on clades B and E, which demonstrated moderate protection against HIV with a 31.2 percent efficacy.

"Vaccine-induced immune responses elicited from this clade B/E-based vaccine regimen induced cross-clade responses in South Africans and, at peak immunogenicity, the South African vaccinees exhibited significantly higher cellular and antibody immune responses than the Thai vaccinees," said Gray.

The HVTN 097 study is part of a larger HIV vaccine research endeavor led by the Pox-Protein Public-Private Partnership, or P5—a diverse group of public and private organizations committed to building on the success of the RV144 trial. The P5 aims to produce an HIV vaccine that could have a significant public health benefit in southern Africa and to advance scientists' understanding of the immune responses associated with preventing HIV infection.

"Since 2009, the HIV vaccine field has been building on findings from RV144 to understand and develop improvements in vaccine breadth and duration in order to protect more people for longer periods of time," said Lt. Col. Julie Ake, principal deputy director of MHRP.

The journey towards an effective HIV vaccine. This material relates to a paper that appeared in the Sep. 18, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by G.E. Gray at University of the Witwatersrand in Johannesburg; South Africa; and colleagues was titled, "Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa." Credit: ©South African Medical Research Council, Produced by JP Crouch for Blue Pear Visuals

T-cell and antibody responses measured

The RV144 vaccine regimen in HVTN 097 vaccinees induced a significantly higher CD4+ T cell rate than seen in the Thai vaccine recipients (RV144=36.4 percent; HVTN 097=51.9 percent), irrespective of age and sex. South African and Thai participants also generated cross-clade against HIV clades AE, B and C, which, in a panel of clade C antigens, were also higher and more prevalent in South Africans. In general, cross-clade immune responses were stronger than expected in South Africa. HVTN 097 is a precursor to studies that adapted the RV144/Thai vaccine regimen to be clade C specific, now underway in South Africa (HVTN 702).

"This breaks open the thought pattern that each region of the world needs a separate type of HIV vaccine based upon their circulating strains," said Larry Corey, M.D., principal investigator of the HVTN.

Associations between BMI and vaccine-induced immune responses

A previous clinical trial (HVTN 503/Phambili) conducted in South Africa demonstrated that higher BMI was associated with a reduction in vaccine-induced immune responses. Given the high rates of obesity in South Africa, the HVTN 097 study team, after stratifying the groups, found that a higher BMI was not associated with a reduced CD4+ T cell and antibody response rate or the strength of the response rate. Notably, CD4 + T cell responses were detected in 100 percent of vaccinees with a BMI greater than 30, giving hope for future HIV vaccine regimens based on the RV144/Thai vaccine regimen.

Differences observed in vaccine-induced immune responses between Thais and South Africans

The study team acknowledge that factors such as race, ethnicity, the microbiome, or genetic factors may have influenced -induced immune responses in South Africans.


Explore further

New sequencing study provides insight into HIV vaccine protection

More information: G.E. Gray el al., "Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa," Science Translational Medicine (2019). stm.sciencemag.org/lookup/doi/ … scitranslmed.aax1880
Journal information: Science Translational Medicine

Provided by HIV Vaccine Trials Network
Citation: Cross-clade immune responses reported in South African RV144 HIV vaccine regimen (2019, September 19) retrieved 14 October 2019 from https://medicalxpress.com/news/2019-09-cross-clade-immune-responses-south-african.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
88 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more